Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
15-hydroxyeicosatetraenoic acid (15-HETE) is a monohydroxy fatty acid metabolite of arachidonic acid produced primarily via the 15-lipoxygenase pathway. It acts as an autocrine and paracrine signaling agent involved in regulating inflammatory responses and has both anti-inflammatory and immunomodulatory effects. In vitro studies show that it inhibits LTB4 formation and neutrophil chemotaxis. Clinically relevant actions include inhibition of angiogenesis and growth in certain cancer cell lines through mechanisms involving reactive oxygen species generation and activation of peroxisome proliferator-activated receptor gamma (PPARγ). It also protects pulmonary artery smooth muscle cells from apoptosis via the inducible nitric oxide synthase (iNOS) pathway[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 15-hydroxyeicosatetraenoic acid.